Special Session

Presidential Symposium II - EL13 - When Chemotherapy Fails, RT Can Cure Hematologic Malignancies without Added Immunomodulation

9/15/2019
10:15 AM - 11:45 AM
Location: Room W193

Session Type: Special Session

Before multi-agent chemotherapy became standard of care for Hodgkin and aggressive B cell lymphoma, radiation alone was used to cure some patients. In the modern era, relapsed and refractory lymphomas present controversial management decisions. With an ever-growing armamentarium of biologic and immunologic agents, including PD1 agents and CAR T cell therapy, the integration of radiation and these exciting therapies is very controversial. We will debate the addition of immune therapies to radiation in the case of relapsed Hodgkin and relapsed diffuse large B cell lymphoma. Please join us!

Presentations:

Carl DeSelm, MD, PhD

Washington University School of Medicine

Presentation(s):

Send Email for Carl DeSelm

Chelsea Pinnix, MD, PhD

MD Anderson Cancer Center

Disclosure:
Employment
MD Anderson Cancer Center: Associate Professor: Employee

Compensation
Global Oncology One: Consultant;
Int J Rad Oncol Biol Physics: Honoraria; Merck and Co: Research Grants

Ownership
Neumentum Inc: Stock

Presentation(s):

Send Email for Chelsea Pinnix

Bouthaina Dabaja, MD

MD Anderson Cancer Center

Disclosure:
Employment
MD Anderson Cancer Center, Division of Radiation Oncology

Presentation(s):

Send Email for Bouthaina Dabaja


Assets

Presidential Symposium II - EL13 - When Chemotherapy Fails, RT Can Cure Hematologic Malignancies without Added Immunomodulation



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Presidential Symposium II - EL13 - When Chemotherapy Fails, RT Can Cure Hematologic Malignancies without Added Immunomodulation